Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.05
-0.0002-0.02%
Volume:539.17K
Turnover:576.70K
Market Cap:229.62M
PE:-0.86
High:1.11
Open:1.04
Low:1.04
Close:1.05
52wk High:3.78
52wk Low:0.8621
Shares:218.73M
Float Shares:157.19M
Volume Ratio:0.26
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2227
EPS(LYR):-1.3222
ROE:-59.60%
ROA:-28.92%
PB:0.60
PE(LYR):-0.79

Loading ...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

GlobeNewswire
·
18 hours ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

THOMSON REUTERS
·
Aug 06

Allogene Therapeutics (ALLO) Receives a Buy from Robert W. Baird

TIPRANKS
·
Aug 05

JPMorgan Downgrades Allogene Therapeutics to Neutral From Overweight

MT Newswires Live
·
Aug 04

U.S. RESEARCH ROUNDUP-Carvana, Federated Hermes, Ralph Lauren

Reuters
·
Aug 04

Allogene Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight

THOMSON REUTERS
·
Aug 04

Allogene Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Aug 02

BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing

Reuters
·
Aug 01

Allogene Therapeutics Inc: None of Co's Trials Open to Enrollment or Pipeline Programs Include Allo-647

THOMSON REUTERS
·
Aug 01

Allogene Therapeutics Inc - Fc Plus Allo-647 Arm Closed Due to Adverse Event - SEC Filing

THOMSON REUTERS
·
Aug 01

Allogene Therapeutics: Will Advance Next-Generation Allocar T Product Candidates Using Proprietary Dagger Platform Technology

THOMSON REUTERS
·
Aug 01

Allogene Therapeutics Announces Launch of ALPHA3 Study Using Standard Fludarabine and Cyclophosphamide for Large B-Cell Lymphoma

Reuters
·
Aug 01

RBC Capital Remains a Buy on Allogene Therapeutics (ALLO)

TIPRANKS
·
Jul 08

Allogene Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 24

Bernstein Reaffirms Their Hold Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
Jun 20

Deborah M. Messemer, Director, Reports Disposal of Allogene Therapeutics Inc. Common Shares

Reuters
·
Jun 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (GB:GSK), Sartorius Stedim Biotech (GB:0RG8) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Jun 11

Allogene Therapeutics (ALLO) Receives a Hold from Bernstein

TIPRANKS
·
Jun 06

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
Jun 02

Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 02